Biogen Alzheimer's drug success: A big step because almost every dementia trial before it has ended in failure
On Thursday night, Biogen announced surprise successful results from an Alzheimer's drug clinical trial that sent shares of the pharmaceutical company soaring.
Alzheimer's drug research has been plagued by years of unrelenting failures, leading companies including Pfizer to give up the search for new compounds.
Dementia experts have questioned the narrow focus from biotech companies on amyloid protein, but the Biogen progress with an amyloid-targeting drug may lead to renewed confidence in the search for similar drugs.
To read more click here